2. Academic Validation
  3. Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development

Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development

  • Bioorg Med Chem Lett. 2006 Jun 15;16(12):3287-91. doi: 10.1016/j.bmcl.2006.03.030.
Harshad K Rami 1,  Mervyn Thompson,  Geoffrey Stemp,  Steve Fell,  Jeffrey C Jerman,  Alexander J Stevens,  Darren Smart,  Becky Sargent,  Dominic Sanderson,  Andrew D Randall,  Martin J Gunthorpe,  John B Davis
Affiliations

Affiliation

  • 1 Neurology and GI CEDD, New Frontiers Science Park, GlaxoSmithKline, Third Avenue, Harlow, Essex CM19 5AW, UK. Harshad.Rami@gsk.com
PMID: 16580202 DOI: 10.1016/j.bmcl.2006.03.030
Abstract

Small molecule antagonists of the vanilloid receptor TRPV1 (also known as VR1) are disclosed. Pyrrolidinyl ureas such as 8 and 15 (SB-705498) emerged as lead compounds following optimisation of the previously described urea SB-452533. Pharmacological studies using electrophysiological and FLIPR-Ca2+-based assays showed that compounds such as 8 and 15 were potent antagonists versus the multiple chemical and physical modes of TRPV1 activation (namely capsaicin, acid and noxious heat). Furthermore, 15 possessed suitable developability properties to enable progression of this compound into in vivo studies and subsequently clinical development.

Figures
Products